VYNE reports Q1 2024 net loss of $6.2M, cash $86M; vitiligo Phase 2b trial on track

VYNE Therapeutics Inc.

2024-Q1 EPS reported -$0.15 revenue$98,000

Cash, equivalents, restricted cash and marketable securities of $86.0M as of March 31; runway through end of 2025.
Net loss $6.2M ($0.15/sh) vs $5.6M ($1.74/sh) in Q1 2023; R&D expense up 35.6% to $3.7M.
Phase 2b trial for VYN201 in nonsegmental vitiligo to enroll ~160 subjects in 1%,2%,3% gel vs vehicle; first dose expected Q2 2024.
IND cleared for oral BET inhibitor VYN202; Phase 1a SAD/MAD starting Q2 2024 with top-line data H2 2024.
Top-line Phase 2b data expected mid-2025; Phase 1b trials in psoriasis and RA planned for H2 2025 if Phase 1a successful.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

VYNE Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $0.1 million, net income $6.2 million, EPS $0.15.

Period: the quarter ended March 31, 2024
Revenue: $0.1 million
Net income: $6.2 million
EPS: $0.15
Result: reported results

Exact text from the filing

financial statements included in VYNE’s Quarterly Report on Form 10-Q filed today for additional discussion on liquidity and capital resources. Revenues. Revenues totaled $0.1 million for each of the three months ended March 31, 2024 and 2023, consisting of royalty revenue from the Company's royalty agreement with LEO Pharma, to whom VYNE previously licensed

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-24-021971

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.